Interferon-beta was compared against methotrexate for idiopathic and multiple sclerosis-associated intermediate uveitis in a small randomized controlled clinical trial that showed superiority of interferon-beta in improving visual acuity and reducing macular edema after 3 months of treatment [33]. The gene discussed is IFNB1; the disease is intermediate uveitis.